Acetazolamide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Acetazolamide
- Pharmacist Assessment Report
- Acetazolamide: Carbonic anhydrase inhibitor → exercise-induced malignant hyperthermia
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Acetazolamide: Carbonic anhydrase inhibitor → exercise-induced malignant hyperthermia
One-Sentence Summary
Acetazolamide is a carbonic anhydrase inhibitor that is marketed in Canada. The TxGNN model predicts it may be effective for exercise-induced malignant hyperthermia, with a score of 0.9995. There are no clinical trials and no publications that directly study this disease, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | exercise-induced malignant hyperthermia |
| TxGNN Prediction Score | 0.9995 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 2 of 3; dormant: 1) |
| Number of DINs | 3 (marketed: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available for acetazolamide. Acetazolamide belongs to the carbonic anhydrase inhibitor class, which alters acid-base balance and ion handling in tissues.
A possible link to exercise-induced malignant hyperthermia, a disorder of muscle physiology, is that these effects might influence muscle ion handling. This idea is speculative. Nothing in the data compiled for this report supports it, and the score of 0.9995 is a model output only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02537893 | ACETAZOLAMIDE FOR INJECTION USP | Not recorded | Not recorded |
| 00545015 | ACETAZOLAMIDE | Not recorded | Not recorded |
| 02358328 | ACETAZOLAMIDE FOR INJECTION, USP | Not recorded | Not recorded |
The approved indication text is not recorded in the local data. All three licences are currently valid single-ingredient products.
Safety Considerations
- Drug Interactions (100 interactions were found; examples shown):
- Major: acetylsalicylic acid, cisapride
- Moderate: antidiabetic agents (e.g. acarbose, acetohexamide, canagliflozin, dapagliflozin, dulaglutide), corticosteroids (e.g. dexamethasone, betamethasone, beclomethasone), amphotericin B formulations, and laxatives (bisacodyl, castor oil)
- Minor: doxycycline
Other safety information should be taken from the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a very high model score but no trials, no literature and no identifiable mechanism. The evidence level is L5.
To proceed, the following is needed:
- Mechanism of action data for acetazolamide
- Preclinical or mechanistic studies linking carbonic anhydrase inhibition to exercise-induced malignant hyperthermia
- Warnings and contraindications from the Health Canada package insert, to complete the safety screening
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.